Reshma Kewalramani, Vertex CEO
FDA lifts hold on Vertex's diabetes stem cell therapy after just two months under the microscope
Vertex Pharmaceuticals has received the FDA go-ahead to continue studies for its diabetes stem cell therapy.
The treatment, which Vertex has attempted to describe as a “cure,” had been on hold at the agency since May, when regulators expressed concerns about a lack of information ahead of the dose escalation portions of the study. With the hold lifted, Vertex will begin enrolling patients again at the high dose level.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
